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Background. Both pandemic and interpandemic influenza is associated with high morbidity and 
mortality worldwide. Seasonal epidemics are caused by both influenza A and B virus strains that 
cocirculate with varying predominance and may give rise to severe illness equally. According to World 
Health Organization recommendations, current annual vaccines are composed of 2 type A and 1 type 
B virus-specific component.  
Methods. As a novel attenuated live vaccine against influenza B virus, we generated a hemagglutinin 
cleavage site mutant of strain B/Lee/40 by replacing the common monobasic cleavage site recognized 
by trypsinlike proteases with an elastase-sensitive site, and we investigated the in vitro properties, 
attenuation, humoral responses, and efficacy in mice.  
Results. This mutant virus replicated in cell culture equally well as the wild type but in a strictly 
elastase-dependent manner. In contrast to the mouse-pathogenic parental virus, the cleavage site 
mutant was fully attenuated in mice and not detectable in their lungs. After 1 intranasal immunization, 
the animals survived lethal challenge with wild-type virus without weight loss or any other signs of 
disease. Furthermore, no challenge virus could be reisolated from the lungs of vaccinated mice.  
Conclusions. These findings demonstrate that proteolytic activation mutants can serve as live 
vaccine against influenza B virus.  
 
 
Among respiratory viruses, influenza A and B viruses pose one of the most significant public health 
problems worldwide, because they cause outbreaks of mild and severe respiratory disease each 
season on a global scale. Both type A and B viruses require interventions due to their effect on public 
health. Although the influenza B virus-associated mortality is lower than that observed with type A 
strains of the H3N2 subtype, it is still higher than with A/H1N1 strains. Moreover, influenza B strains 
become the major cause of the seasonal epidemics every 2–4 years [1].  
Current established inactivated or live attenuated vaccines against seasonal influenza contain 2 type 
A and 1 type B component addressing the cocirculation of A/H1, A/H3, and type B virus strains. 
Although the hemagglutinin (HA) evolution rate of influenza B viruses is slower than in influenza A 
viruses, single amino acid changes can be sufficient for antigenic escape, most likely owing to a 
smaller number of nonoverlapping epitopes forming one continuous antigenic site [2–8].  
Furthermore, beside antigenic drift, the emergence of new influenza B strains is driven by insertion-
deletion mutations and reassortment [9]. In particular since the late 1980s, the coexistence of 2 
alternating HA lineages named after their prototype strains B/Victoria/2/87 and B/Yamagata/16/88 
complicates the epidemiologic assessment. In some years a single lineage predominates, whereas in 
others both cocirculate [3, 7]. Such unpredictable prevalences led to a vaccine mismatch in 5 of 10 
  
seasons between 2000 and 2010, meaning that the predominant influenza B virus strain belonged to 
the opposite HA lineage of the selected vaccine strain, resulting in low cross-protection and reduced 
efficacy [10–12].  
To resolve those problems, the inclusion of 2 type B components in the yearly influenza vaccine—that 
is, a quadrivalent seasonal vaccine instead of the conventional trivalent preparation—had been 
proposed [10]. However, this concept involves more complex production and licensing procedures 
plus a decrease in vaccination doses available. An alternative could be an attenuated live vaccine, 
such as the cold-adapted [13–15], the NS1-deleted [16, 17], or the HA cleavage site mutants [18, 19]. 
The HA cleavage site is a promising target for virus attenuation, because activation cleavage of the 
HA0 precursor into the HA1 and HA2 fragments by host proteases is an essential step in the 
replication cycle of all influenza A and B virus strains [20, 21].  
Only the cleaved HA can undergo a conformational change in the acidic milieu of the endosome after 
receptor-mediated endocytosis to expose the hydrophobic N terminus of the HA2 fragment for 
mediating fusion between endosomal and virion membranes [22–25]. Attenuated influenza A viruses 
that contained in their HA an elastase cleavage motif, were tested successfully elsewhere in mice and 
swine, relevant influenza virus hosts [18, 19, 26–28].  
Whereas overall structure and domain organization of the HA from type A and B viruses are very 
similar, their sequence identity is as low as ∼20% [6]. In contrast to influenza A viruses [29], influenza 
B viruses do not become susceptible to furin activation after introduction of a polybasic cleavage site 
into HA [30]. Thus, there seem to be differences between influenza A and B viruses in the interaction 
of HA and activating proteases. Correspondingly, it remained an open question whether a cleavage 
site alteration of the type B virus HA would completely switch the proteolytic activation to another 
protease, resulting in strict dependence on that alternative enzyme. In this study, we generated an 
elastase cleavage site mutant from strain B/Lee/40 by reverse genetics to investigate its in vitro 






The 293T human embryonic kidney cells were cultured in Dulbecco minimal essential medium (MEM) 
containing 10% fetal calf serum. Madin-Darby canine kidney (MDCK) cells were grown in MEM 
supplemented with 10% fetal calf serum.  
 
Recombinant Viruses 
For generation of recombinant influenza B viruses, we used for cotransfection the plasmids encoding 
all 8 genes of strain B/Lee/40, as described elsewhere [31]. Each gene segment is integrated into the 
pHW2000 plasmid vector [32] under control of the human RNA polymerase I promoter and mouse 
RNA polymerase I terminator and a truncated RNA polymerase II (immediate-early CMV) promoter. 
For rescue of wild-type B/Lee40-Wt, we used the original plasmids.  
To engineer the elastase cleavage site, we replaced Arg-361 in the HA with valine or alanine by 
changing the nucleotides at positions 1114 and 1115 (corresponding to the published HA sequence 
with accession number FLBHAOA) from AG to GT or GC, respectively, using the QuikChange Kit 
(Stratagene). Primer sequences are available on request.  
 
Virus Propagation and Titration 
For propagation of B/Lee-Wt and the elastase cleavage site mutants on MDCK cells in MEM 
containing 0.2% bovine serum albumin, we used 2.0 μg/mL N-tosyl-l-phenylalanine chloromethyl 
ketone (TPCK)–treated trypsin (Sigma) or 5 μg/mL porcine pancreatic elastase (Serva 
Electrophoresis), respectively. We performed the plaque assays on MDCK cell monolayers essentially 
as described elsewhere [33]. For the elastase-dependent mutants, we used elastase instead of TPCK-
  
treated trypsin in the plaque overlay. For growth curves, we inoculated MDCK cells with virus at 
multiplicity of infection of 10
−2
 and determined the virus titer by plaque assay in the presence of the 
appropriate protease in 2 independent experiments. Formalin inactivation of virus was performed as 
described elsewhere [18].  
 
Western Blot Analysis 
We infected confluent MDCK monolayers, grown in 6-cm dishes, with virus at a multiplicity of infection 
of 10. All viruses were incubated in the presence of either TPCK-treated trypsin or elastase, or without 
any protease, for 16 hours in MEM containing 0.2% bovine serum albumin.  
After sodium dodecyl sulfate–polyacrylamide gel electrophoresis (10%) from pelleted supernatants, we 
used a monoclonal antibody to influenza B virus HA (Acris; 1:250; 1 hour at room temperature) and a 
mouse immunoglobulin (Ig) G–specific monoclonal antibody, conjugated with horseradish peroxidase 
as secondary antibody (Dako; 1:250; 1 hour at room temperature) followed by chemiluminescence 
(Supersignal West Pico Chemiluminescent Substrate Kit; Pierce).  
 
Animal Experiments 
Four-week-old female Balb/C mice (Charles River) were inoculated intranasally with 20 or 70 μL of 
B/Lee40-Ala or B/Lee40-Wt under anesthesia after an intramuscular injection of ketamine 
hydrochloride at a dosage of 200 mg/kg. At 12 hours or 1, 3, or 5 days after inoculation, we killed the 
animals by cervical dislocation and removed the entire organs (heart, lung, brain).  
After homogenization in 1 mL of phosphate-buffered saline (PBS), we determined the organ titers by 
plaque assay in the presence of the appropriate protease in the overlay (333 μL of inoculum in plaque 
assay). Animal experiments were performed according to the German animal welfare legislation. All 
animal protocols had been approved by the relevant German authority.  
 
Serum IgG Enzyme-Linked Immunosorbent Assay and Virus Neutralization Assay 
We detected serum IgG antibodies by enzyme-linked immunosorbent assay. First, we coated 
Maxisorp 96-well plates (Nunc) with total B/Lee40-Wt virus protein at 4°C overnight. Then we detected 
the bound antibodies by mouse-specific IgG labeled with horseradish peroxidase (BD Pharmingen) 
and BM Blue POD substrate (Roche Diagnostics). Finally, we expressed the titers as the reciprocal of 
the dilution that yielded an optical density of 0.1. The virus neutralization test was performed after heat 
inactivation of the mouse serum samples at 56°C for 30 minutes.  
First, we prediluted the inactivated serum samples at 1:10 and then we diluted them 2-fold serially and 
incubated them with 50 plaque-forming units (PFU) of virus for 1 hour at 37°C. Afterward, we infected 
MDCK cells (grown on 48-well plates) with the virus-serum mixtures, incubated the cells for 2 days, 
and determined the hemagglutination titers of supernatants from all wells. The highest serum dilution 
at which the hemagglutination test still gave a negative result is the virus neutralization titer. For 




Generation of Recombinant Viruses by Reverse Genetics 
Proteolytic activation of the HA of influenza B viruses involves the cleavage of the precursor HA0 into 
the HA1 and HA2 fragments by trypsinlike host proteases [21], which require a monobasic cleavage 
motif. Using site-directed mutagenesis, we generated 2 protease activation mutants of the mouse-
adapted influenza virus strain B/Lee/40 by replacing the arginine at the HA cleavage site at amino acid 
position 361 (corresponding to nucleotides 1114–1115) with valine or alanine.  
These amino acids, followed by the conserved glycine of the N-terminus of HA2, form a motif 
susceptible to porcine pancreatic elastase [34]. For generation of the recombinant viruses by reverse 
genetics, we cotransfected the respective HA plasmid encoding either the wild type or the mutant 
  
together with plasmids expressing the other 7 gene segments [31], resulting in virus progeny B/Lee40-
Wt and the 2 protease activation mutants B/Lee40-Val and B/Lee40-Ala (Figure 1A).  
 
Replication of HA Cleavage Site Mutants In Vitro Is Strictly Dependent on Elastase 
Proteolytic activation of the HA is essential for multicycle replication of influenza viruses [21], as 
indicated by plaque formation. To study the dependence of B/Lee40-Val and B/Lee40-Ala on 
exogenous proteases, we performed plaque assays on MDCK cells with elastase or trypsin or without 
any exogenous protease. Whereas the parental B/Lee40-Wt yielded visible plaques in the presence of 
trypsin, both mutants B/Lee40-Val and B/Lee40-Ala formed plaques only in the presence of elastase 
(Figure 1B). Correspondingly, Western blot analysis demonstrated the susceptibility of HA0 of 
B/Lee40-Val and B/Lee40-Ala to elastase (Figure 1C).  
The appearance of cleavage products in the presence of trypsin can presumably be attributed to 
arginine or lysine residues in the vicinity of the cleavage site (positions 350, 352, 356, and 359). 
Likewise, the HA of the parental B/Lee40-Wt was partially cleaved by elastase, probably because of 
glycine residues adjacent to the cleavage site (positions 348, 362, 365, and 369). However, this 
cleaved HA is not fusion competent, as indicated by the plaque assay (Figure 1B). Cleavage of 
B/Lee40-Wt HA0 can be observed to a minimal extent in the absence of any exogenous protease, 
suggesting either detection of inoculum at minute amounts or low expression of a trypsinlike protease 
with monobasic specificity in MDCK cells (Figure 1C).  
To study growth kinetics, MDCK cells were infected with B/Lee40-Wt in the presence of trypsin and 
with the cleavage site mutants B/Lee40-Val and B/Lee40-Ala in the presence of elastase. Whereas 
B/Lee-Val reached somewhat lower titers than B/Lee40-Wt, B/Lee40-Ala grew as well as the parental 
wild type in cell culture (Figure 1D). Taken together, the replacement of the monobasic cleavage site 
of the wild-type HA by an elastase motif leads to a strict dependence of viral growth on the addition of 
elastase to the culture medium. Furthermore, in the presence of elastase, the protease activation 
mutant B/Lee40-Ala demonstrated in vitro replication properties equivalent to its parental virus.  
 
B/Lee40-Ala Is Attenuated in Mice 
To assess the impact of the cleavage site alterations on virulence, we inoculated mice intranasally with 
10
6
 PFU (in 70 μL) of B/Lee40-Wt or B/Lee40-Ala. Animals infected with the former (n = 5) developed 
severe weight loss and died, whereas mice that had received the latter (n = 4) did not display any 
signs of disease or any weight loss (Figure 2A).  
To assess the viral load, we determined viral titers in lungs at 12 hours or 1, 3, or 5 days after 
inoculation from 2 mice infected with 10
6
 PFU (in 70 μL) by plaque assay, beginning with undiluted 
organ homogenate. The parent virus B/Lee40-Wt reached a titer of ∼10
7
 PFU/lung after 12 hours, 
which subsequently remained at this level. In contrast to its wild type, B/Lee40-Ala was not detected in 
the lungs of infected animals at any time point studied (Figure 2B). These observations support the 
notion that the protease activation mutant B/Lee40-Ala is severely restricted in in vivo replication and 
fully attenuated in mice.  
 
Protection Against Lethal Challenge 
To investigate the potential of B/Lee40-Ala to serve as live vaccine, we inoculated mice intranasally 
with either PBS (n = 8; 20 μL), formalin-inactivated B/Lee40-Ala (n = 3; 10
6
 PFU in 70 μL) before 
inactivation), or live B/Lee40-Ala at dosages of 10
3
 (n = 6), 10
4
 (n = 7), 10
5
 (n = 8), or 10
6
 PFU (n = 8) 
(in 20 μL for all dosages) and challenged them 4 weeks later with a lethal dose of B/Lee-Wt (10
6
 PFU 
in 70 μL) Six of 8 mock-immunized animals died. No animal that had received the inactivated B/Lee40-
Ala preparation survived.  
Two of 6 mice survived after immunization with 10
3
 PFU B/Lee40-Ala. The surviving animals had 
severe weight loss and recovered during the observation period to a negligible extent (Figure 3A). In 






 PFU B/Lee40-Ala survived (Table 1) without 
weight loss (Figure 3A) or any other signs of disease. To study the viral load after challenge, we killed 
2 mice from each group 3 days after challenge, and determined viral titers from their lungs beginning 
with undiluted homogenate. The mice that had received PBS, inactivated B/Lee40-Ala, or 10
3
 PFU live 
B/Lee40-Ala demonstrated virus titers of ∼10
6








 PFU of live virus displayed no detectable challenge virus in their lungs 
(Figure 3B), corresponding with the absence of symptoms. Taken together, these data demonstrate 
that the attenuated protease activation mutant B/Lee40-Ala can prevent infection and disease after 
lethal influenza B virus challenge.  
  
Induction of Neutralizing Serum Antibodies 
To determine the induction of serum antibodies, we inoculated mice intranasally (20 μL) with either 
PBS (n = 1); 10
3
 (n = 4), 10
4
 (n = 3), 10
5
 (n = 5), or 10
6
 PFU (n = 5) of B/Lee40-Ala; or 10
4
 PFU of 





PFU of B/Lee-Ala or with PBS displayed low or no detectable serum IgG and virus neutralization titers, 
respectively.  




 PFU of B/Lee40-Ala had notable serum titers (Figure 4A 
and 4B). The considerably higher serum IgG and neutralization titers after immunization with 10
4
 PFU 
of B/Lee40-Wt could be attributed to prolonged replication at higher titers compared with B/Lee40-Ala 
(Figure 2B).  
 
Discussion 
Besides influenza A viruses, which perpetuate annual epidemics and have pandemic potential, the 
type B viruses are a major cause for seasonal influenza [1, 8]. Thus, conventional inactivated and 
cold-adapted live vaccines [13–15] include 2 type A and 1 type B components [35, 36]. However, the 
influenza B virus HA has split up into 2 different antigenic lineages in the late 1980s [3, 7]. Since then, 
the frequent lineage mismatch of the vaccine to the predominant strain has led to considerably 
reduced efficacy and effectiveness, because the type B component selected did not induce complete 
cross-protection against both lineages [10, 11].  
Moreover, substantial antigenic differences between vaccine and circulating viruses may result in 
enhanced disease as demonstrated with an inactivated vaccine against type A viruses and 
homosubtypic challenge in pigs [37, 38]; the relevance of this problem in humans remains to be 
investigated. Furthermore, the induction of heterosubtypic immunity in mice and ferrets against 
influenza A viruses was found to be diminished by previous application of an inactivated vaccine, in 
contrast to prior infection with live virus [39–41].  
Alternatives may be attenuated live vaccines like the cold-adapted [13–15], NS1-deleted [16, 17], or 
HA cleavage site mutants [18, 19]. The altered HA cleavage motif results in attenuation by strict 
dependence on a protease not accessible to the virus in vivo, leading to an effective block in virus 
propagation. Protease activation mutants requiring elastase had been generated from influenza A 
viruses and investigated in mice (mouse-adapted H1N1, high-pathogenic laboratory H7N7 strains and 
corresponding reassortants) and in pigs (H1N1 swine influenza virus). Those attenuated viruses 
elicited protection against homologous, homosubtypic, and heterosubtypic challenges, probably 
because they strongly activated both humoral and cell-based immune responses [18, 19, 26, 42].  
In the current study, we investigated the suitability of HA cleavage site mutants as attenuated live 
vaccine against influenza B virus. Accordingly, we replaced the arginine at the HA cleavage site of the 
strain B/Lee/40 with valine or alanine, resulting in an elastase cleavage site motif [34]. Both mutants 
were proved to undergo strictly elastase-dependent multicycle replication.  
Because the alanine mutant replicated in cell culture to the same titer as the parental unmodified virus, 
we further studied its in vivo properties and immunogenicity. In contrast to the wild-type parental virus, 
which is pathogenic for mice, this mutant was fully attenuated and not detectable in the lungs after 
inoculation of mice in a dose escalation study. After a single intranasal immunization, the mice 
survived a lethal challenge with wild-type virus without weight loss or other signs of disease, and no 
challenge virus was detected in lungs.  
A frequent concern against the use of an influenza live attenuated vaccine is reversion or pseudo-
reversion to a virulent phenotype. Previous passaging experiments with an elastase mutant from the 
influenza A virus strain A/WSN/33 (H1N1) indicated a reversion frequency of ∼10
−7
 [18]. We expect a 
similar probability of influenza B virus revertants, because the mutation rates are of the same 
magnitude for type A and B viruses [43]. Hence, the modified HA cleavage site should be combined 
with other attenuating modifications, such as cold adaptation or NS1 deletion [16, 17].  
  
Immune escape as a result of even minor antigenic HA changes is a typical feature of the influenza B 
virus [3–5, 7] and is largely attributed to a smaller number of nonoverlapping epitopes forming one 
continuous antigenic site [2, 6, 8]. A live vaccine delivering both HA and the more conserved internal 
proteins might counterbalance this major shortcoming by induction of strong cell-mediated immunity, 
especially in elderly people in whom the protection against influenza A virus infection is mediated by 
effector T cells rather than antibodies [44, 45].  
However, the frequent HA lineage mismatch has led to decreased efficacy of both the inactivated 
vaccines and the established cold-adapted live vaccines [11, 12]. Therefore, reliable stimulation of a 
protective cell-mediated response by an attenuated live vaccine might require 2 subsequent 
applications, as demonstrated for the elastase HA cleavage site mutant from the swine influenza A 
virus [26–28]. Cross-protection against heterologous type B strains in mice has been demonstrated for 
2 attenuated live vaccines: the NS1-deleted and the cold-adapted attenuated mutants [46, 47]. 
However, in humans, the established cold-adapted live vaccine proved to not be cross-protective in 
case of HA lineage mismatch [10, 11].  
At first view, those 2 findings seem contradictory ; however, a common feature of the mouse model is 
protection against drifted and even heterosubtypic strains after previous infection with live virus [19, 
48]. Therefore, the potential of a type B cleavage site vaccine to elicit HA lineage-independent 
protection remains to be investigated in suitable animal models or even in human volunteers. Another 
possibility to counteract the lineage mismatch would be the proposed quadrivalent seasonal vaccine 
[10]. To avoid a reduction in available vaccine doses, however, this concept is probably more feasible 
with live vaccines, because considerably less antigen is required per dose than with inactivated 
vaccine preparations [18, 49].  
Taken together, our data demonstrate that a protease activation mutant of influenza B virus is strictly 
elastase dependent and replicates as well as wild-type virus in vitro but is fully attenuated and can 
confer protection against infection and disease after lethal challenge in mice. Furthermore, the strict 
dependence on elastase would prevent establishment of the HA gene from the vaccine strain in the 
gene pool of circulating viruses, thereby restricting the emergence of novel HA reassortants.  
In conclusion, our study indicates that HA cleavage site alteration for generation of live vaccines is 
feasible for both influenza A and B viruses.  
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Tables and Figures 
 





Number of surviving mice and total number of mice challenged with 10
6
 plaque-forming units (PFU) of 
B/Lee40-Wt 4 weeks after intranasal immunization. 
  
Figure 1. Recombinant influenza B viruses, B/Lee40-Wt, B/Lee40-Val, and B/Lee40-Ala, with their 
cleavage sites and in vitro phenotypes. A, Scheme of the hemagglutinin (HA) cleavage site region. B, 
Plaque assay on Madin-Darby canine kidney (MDCK) cells in the presence of either elastase or trypsin 
or in the absence of an exogenous protease. C, Western blot analysis of lysates from MDCK cells 
infected with the indicated viruses in the absence of an exogenous protease or in the presence of 
either trypsin or elastase. D, Growth curves of B/Lee40-Wt (circles) in the presence of trypsin and of 
B/Lee40-Val (diamonds) or B/Lee40-Ala (squares) in the presence of elastase. Abbreviation: PFU, 






Figure 2. Viral pathogenicity and lung titers in mice. A, Weight curves from mice inoculated 
intranasally with 10
6
 plaque-forming units (PFU) of either B/Lee40-Wt (circles) or B/Lee40-Ala 
(squares). B, Plaque assays from lungs taken 12 hours and 1, 3, and 5 days after intranasal 
inoculation with 10
6






Figure 3. Immunization with B/Lee40-Ala confers protection against lethal challenge with B/Lee40-Wt. 
A, Average weight loss of mice challenged with 10
6
 plaque-forming units (PFU) of B/Lee40-Wt 4 







down triangles), or 10
3
 (right-side-up triangles) PFU; formalin-inactivated B/Lee40-Ala (filled circles); 
or phosphate-buffered saline (PBS) (open circles). B, Virus titers in lungs from 2 mice in each group at 




Figure 4. Humoral responses in mice after immunization, including immunoglobulin (Ig) G (A) and 
virus neutralization (B) titers from mice serum samples 4 weeks after mock-immunization with 









PFU or B/Lee40-Wt at 10
4
 PFU.  
 
 
